← Evidence map

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026

Commentary: Lysosomal enzymes engineered to cross the blood-brain barrier are reshaping the therapeutic landscape of neuronopathic mucopolysaccharidoses.

Nicolina Cristina Sorrentino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Full record →Abstract, authors, funding and every citing paper · PMID 41162203